Literature DB >> 18494899

A double-blind randomized vehicle-controlled clinical trial investigating the effect of ZnPTO dose on the scalp vs. antidandruff efficacy and antimycotic activity.

P Bailey1, C Arrowsmith, K Darling, J Dexter, J Eklund, A Lane, C Little, B Murray, A Scott, A Williams, D Wilson.   

Abstract

Dandruff is a common problem in approximately 30% of the world's population. Reports in the literature regarding treatment of this condition with various antidandruff shampoos usually report the level of active ingredient within the formulation. However, we propose that a more important parameter relating to antidandruff efficacy is the amount of active ingredient delivered to the scalp from the shampoo. This report describes the results from two studies designed to investigate the relationship between the level of zinc pyrithione (ZnPTO) deposited onto the scalp and the resultant scalp condition. A double-blind randomized vehicle-controlled clinical study comparing three shampoos - a vehicle, a low-depositing ZnPTO shampoo and a high-depositing ZnPTO shampoo - was carried out in the U.K. with 53 panelists with dandruff or mild-to-moderate seborrheic dermatitis of the scalp. Both shampoos containing ZnPTO were significantly superior in antidandruff efficacy to the vehicle. Furthermore, the high-depositing ZnPTO shampoo was significantly superior compared with the low-depositing ZnPTO shampoo in terms of both antidandruff efficacy and antimycotic activity. Antidandruff performance and antimycotic activity of ZnPTO-containing shampoos is highly dependent on the amount of active ingredient delivered to the scalp. Furthermore, careful manipulation of the formulation parameters of an antidandruff shampoo can result in enhanced levels of delivery of the active ingredient without having to increase the level of active ingredient within the formulation.

Entities:  

Year:  2003        PMID: 18494899     DOI: 10.1046/j.1467-2494.2003.00183.x

Source DB:  PubMed          Journal:  Int J Cosmet Sci        ISSN: 0142-5463            Impact factor:   2.970


  9 in total

1.  Pyrithione-zinc Prevents UVB-induced Epidermal Hyperplasia by Inducing HIF-1alpha.

Authors:  Young-Suk Cho; Kyung-Hoon Lee; Jong-Wan Park
Journal:  Korean J Physiol Pharmacol       Date:  2010-04-30       Impact factor: 2.016

2.  Zinc pyrithione impairs zinc homeostasis and upregulates stress response gene expression in reconstructed human epidermis.

Authors:  Sarah D Lamore; Georg T Wondrak
Journal:  Biometals       Date:  2011-03-22       Impact factor: 2.949

Review 3.  Seborrhoeic dermatitis of the scalp.

Authors:  Luigi Naldi; Janouk Diphoorn
Journal:  BMJ Clin Evid       Date:  2015-05-27

Review 4.  Topical treatments for scalp psoriasis.

Authors:  Richard B Warren; Benjamin C Brown; Christopher E M Griffiths
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  The topical antimicrobial zinc pyrithione is a heat shock response inducer that causes DNA damage and PARP-dependent energy crisis in human skin cells.

Authors:  Sarah D Lamore; Christopher M Cabello; Georg T Wondrak
Journal:  Cell Stress Chaperones       Date:  2009-10-07       Impact factor: 3.667

Review 6.  Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.

Authors:  Xin Chen; Qianqian Yang; Lu Xiao; Daolin Tang; Q Ping Dou; Jinbao Liu
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

7.  Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.

Authors:  Chong Zhao; Xin Chen; Changshan Yang; Dan Zang; Xiaoying Lan; Siyan Liao; Peiquan Zhang; Jinjie Wu; Xiaofen Li; Ningning Liu; Yuning Liao; Hongbiao Huang; Xianping Shi; Lili Jiang; Xiuhua Liu; Q Ping Dou; Xuejun Wang; Jinbao Liu
Journal:  Oncotarget       Date:  2017-02-21

Review 8.  Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

Authors:  Huanjie Yang; Xin Chen; Kai Li; Hassan Cheaito; Qianqian Yang; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Semin Cancer Biol       Date:  2019-12-26       Impact factor: 15.707

9.  Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial.

Authors:  C S L Kamamoto; A S Nishikaku; O F Gompertz; A S Melo; K M Hassun; E Bagatin
Journal:  Dermatoendocrinol       Date:  2017-10-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.